7.49
+0.94(+14.35%)
Currency In USD
| Previous Close | 6.55 |
| Open | 6.6 |
| Day High | 7.51 |
| Day Low | 6.53 |
| 52-Week High | 12.4 |
| 52-Week Low | 3.5 |
| Volume | 1.65M |
| Average Volume | 1.05M |
| Market Cap | 462.58M |
| PE | 19.21 |
| EPS | 0.39 |
| Moving Average 50 Days | 5.25 |
| Moving Average 200 Days | 5.45 |
| Change | 0.94 |
If you invested $1000 in Monte Rosa Therapeutics, Inc. (GLUE) since IPO date, it would be worth $353.64 as of September 28, 2025 at a share price of $7.49. Whereas If you bought $1000 worth of Monte Rosa Therapeutics, Inc. (GLUE) shares 3 years ago, it would be worth $900.24 as of September 28, 2025 at a share price of $7.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
GlobeNewswire Inc.
Sep 15, 2025 11:00 AM GMT
Novartis receives an exclusive license to an undisclosed discovery target Novartis also receives options to license two programs from Monte Rosa’s growing preclinical immunology portfolio Monte Rosa to receive an upfront payment of $120 million, plu
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Sep 02, 2025 11:00 AM GMT
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticip